NCT04895722
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 109 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 33 words Show 6 more changesShow less
- Trial completed
- Study completion date changed from estimate of Aug 6, 2026 to Aug 7, 2026
- Interventions: MK-4830 (Biological), Pembrolizumab (Biological), Pembrolizumab/Favezelimab (Biological), Pembrolizumab/Quavonlimab (Biological)… to MK-4830 (Biological), Pembrolizumab (Biological), Pembrolizumab/Favezelimab (Biological), Pembrolizumab/Quavonlimab (Biological)…
- Secondary endpoints: details revised at 8 of 8 entries
- Site details revised at 11 of 109 sites
- Publications: details revised at 1 of 1 entry
- Minor Study completion date: Aug 13, 2026 to Aug 6, 2026
- Study title revised
- Notable Results first posted: Jun 8, 2026
- Trial arms changed: 5 → 7
- Secondary endpoints revised (8)
- Primary endpoint revised
- Minor Secondary endpoints: details revised at 8 of 8 entriesv106
- Minor Study completion date: Jun 25, 2026 to Aug 13, 2026v105
Show 44 earlier versionsHide 44 earlier versions
- Minor Study completion date: Apr 30, 2026 to Jun 25, 2026v104
- Minor Enrollment target: estimated 320 to confirmed 302
- Primary completion date changed from estimate of Jun 30, 2026 to May 21, 2025
- Study completion date: Jun 30, 2027 to Apr 30, 2026
- Notable Primary completion date: Oct 20, 2025 to Jun 30, 2026
- Study completion date: Nov 18, 2025 to Jun 30, 2027
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 109 of 109 sites
- Minor Study sites revised (109)v99
- Minor Site details revised at 1 of 109 sitesv98
- Minor Study sites: 108 to 109v97
- Minor Site details revised at 1 of 108 sitesv96
- Minor Primary completion date: Sep 28, 2025 to Oct 20, 2025
- Study completion date: Oct 28, 2025 to Nov 18, 2025
- Minor Study sites revised (108)v94
- Minor Site details revised at 5 of 108 sitesv93
- Minor Site details revised at 2 of 108 sitesv92
- Minor Site contacts updated at 1 of 108 sitesv91
- Minor Site details revised at 1 of 108 sitesv90
- Minor Site details revised at 3 of 108 sitesv89
- Minor Site details revised at 2 of 108 sitesv88
- Minor Site details revised at 2 of 108 sitesv87
- Minor Study sites: 106 to 108v86
- Minor Site details revised at 1 of 106 sitesv85
- Minor Site details revised at 2 of 106 sitesv84
- Minor Site details revised at 2 of 106 sitesv83
- Minor Site details revised at 1 of 106 sitesv82
- Minor Site details revised at 3 of 106 sitesv81
- Minor Site details revised at 2 of 106 sitesv80
- Minor Study sites: 105 to 106v79
- Notable Eligibility criteria revised
- Study sites: 103 to 105
- Study title revised
- Minor Site details revised at 1 of 103 sitesv77
- Minor Site details revised at 1 of 103 sitesv76
- Minor Study sites: 102 to 103v75
- Minor Study sites: 100 to 102v74
- Minor Study sites: 98 to 100v73
- Minor Study sites: 95 to 98v72
- Minor Study sites: 94 to 95v71
- Minor Study sites: 93 to 94v70
- Minor Site details revised at 1 of 93 sitesv69
- Minor Study sites: 90 to 93v68
- Minor Study sites: 87 to 90v67
- Minor Study sites: 86 to 87v66
- Minor Study sites: 84 to 86v65
- Minor Study sites: 83 to 84v64
- Minor Study sites: 82 to 83v63
- Minor Study sites: 81 to 82v62
- Minor Study sites: 79 to 81v61
- Minor Study sites: 76 to 79v60
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Participants in Cohort A receive co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) every 6 weeks (Q6W) for up to approximately 2 years.
Participants in Cohort A receive pembrolizumab 400 mg intravenously (IV) Q6W for up to approximately 2 years.
Participants received co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) Q6W for up to approximately 2 years.
Participants receive pembrolizumab 200 mg plus MK-4830 800 mg Q3W for up to approximately 2 years.
Participants receive co-formulated pembrolizumab/favezelimab (200 mg/800 mg) every 3 weeks (Q3W) for up to approximately 2 years.
Participants receive co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) Q3W for up to approximately 2 years.
Participants in Cohort B receive pembrolizumab 400 mg IV Q6W for up to approximately 2 years.
Biologicals: Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab, Pembrolizumab/Vibostolimab, MK-4830
Sites
109 sites in 22 countries
United States 11, Spain 8, Colombia 7, Germany 7, South Korea 7, France 6, Hungary 6, Poland 6, Russia 6, Belgium 5, Guatemala 5, Turkey (Türkiye) 5, Denmark 4, Greece 4, Romania 4, United Kingdom 4, Canada 3, Italy 3, Lithuania 3, Costa Rica 2, Estonia 2, Netherlands 1